Endonovo Therapeutics, Inc. (ENDV)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 7.07 Million USD | -1.15% |
| 2022 | 7.15 Million USD | 0.82% |
| 2021 | 7.09 Million USD | 7.17% |
| 2020 | 6.62 Million USD | -3.25% |
| 2019 | 6.84 Million USD | 15.1% |
| 2018 | 5.94 Million USD | 27.99% |
| 2017 | 4.64 Million USD | 131.2% |
| 2016 | 2 Million USD | 33.51% |
| 2015 | 1.5 Million USD | 6.34% |
| 2014 | 1.41 Million USD | 87.79% |
| 2013 | 753.63 Thousand USD | 162.72% |
| 2012 | 286.85 Thousand USD | 511.45% |
| 2011 | -69.71 Thousand USD | -100.5% |
| 2010 | -34.77 Thousand USD | 30.46% |
| 2009 | -50 Thousand USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 7.01 Million USD | -0.61% |
| 2024 Q1 | 7.05 Million USD | -0.18% |
| 2023 Q3 | 7.05 Million USD | 0.89% |
| 2023 Q2 | 6.99 Million USD | 1.52% |
| 2023 Q4 | 7.07 Million USD | 0.2% |
| 2023 FY | 7.07 Million USD | -1.15% |
| 2023 Q1 | 6.88 Million USD | -3.69% |
| 2022 Q1 | 7.23 Million USD | 1.94% |
| 2022 FY | 7.15 Million USD | 0.82% |
| 2022 Q4 | 7.15 Million USD | -0.88% |
| 2022 Q3 | 7.21 Million USD | -1.9% |
| 2022 Q2 | 7.35 Million USD | 1.71% |
| 2021 Q4 | 7.09 Million USD | 4.87% |
| 2021 FY | 7.09 Million USD | 7.17% |
| 2021 Q2 | 6.65 Million USD | 0.01% |
| 2021 Q1 | 6.65 Million USD | 0.44% |
| 2021 Q3 | 6.76 Million USD | 1.73% |
| 2020 Q4 | 6.62 Million USD | 8.56% |
| 2020 Q1 | 6.18 Million USD | -9.69% |
| 2020 FY | 6.62 Million USD | -3.25% |
| 2020 Q2 | 6.2 Million USD | 0.33% |
| 2020 Q3 | 6.09 Million USD | -1.65% |
| 2019 Q2 | 6.23 Million USD | 0.27% |
| 2019 Q1 | 6.21 Million USD | 4.58% |
| 2019 FY | 6.84 Million USD | 15.1% |
| 2019 Q3 | 7.12 Million USD | 14.33% |
| 2019 Q4 | 6.84 Million USD | -3.99% |
| 2018 FY | 5.94 Million USD | 27.99% |
| 2018 Q4 | 5.94 Million USD | -9.53% |
| 2018 Q3 | 6.57 Million USD | 8.34% |
| 2018 Q2 | 6.06 Million USD | 13.02% |
| 2018 Q1 | 5.36 Million USD | 15.54% |
| 2017 Q1 | 1.89 Million USD | -5.73% |
| 2017 Q2 | 2.35 Million USD | 24.37% |
| 2017 Q3 | 2.66 Million USD | 13.01% |
| 2017 Q4 | 4.64 Million USD | 74.48% |
| 2017 FY | 4.64 Million USD | 131.2% |
| 2016 Q3 | 1.8 Million USD | 15.25% |
| 2016 FY | 2 Million USD | 33.51% |
| 2016 Q4 | 2 Million USD | 11.41% |
| 2016 Q2 | 1.56 Million USD | 7.19% |
| 2016 Q1 | 1.45 Million USD | -3.0% |
| 2015 Q3 | 1.49 Million USD | 14.78% |
| 2015 Q1 | 1.3 Million USD | -7.73% |
| 2015 FY | 1.5 Million USD | 6.34% |
| 2015 Q4 | 1.5 Million USD | 0.69% |
| 2015 Q2 | 1.3 Million USD | -0.27% |
| 2014 Q3 | 1.18 Million USD | -4.05% |
| 2014 FY | 1.41 Million USD | 87.79% |
| 2014 Q4 | 1.41 Million USD | 19.04% |
| 2014 Q1 | 955.52 Thousand USD | 26.79% |
| 2014 Q2 | 1.23 Million USD | 29.68% |
| 2013 Q4 | 753.63 Thousand USD | 40.31% |
| 2013 FY | 753.63 Thousand USD | 162.72% |
| 2013 Q1 | 320.5 Thousand USD | 11.73% |
| 2013 Q2 | 487.98 Thousand USD | 52.26% |
| 2013 Q3 | 537.13 Thousand USD | 10.07% |
| 2012 Q4 | 286.85 Thousand USD | -78.22% |
| 2012 FY | 286.85 Thousand USD | 511.45% |
| 2012 Q1 | 1.11 Million USD | 20.98% |
| 2012 Q2 | 1.15 Million USD | 3.67% |
| 2012 Q3 | 1.31 Million USD | 14.13% |
| 2011 FY | -69.71 Thousand USD | -100.5% |
| 2011 Q3 | -100 Thousand USD | 0.0% |
| 2011 Q4 | 920 Thousand USD | 1020.0% |
| 2010 FY | -34.77 Thousand USD | 30.46% |
| 2010 Q4 | -30 Thousand USD | 0.0% |
| 2009 FY | -50 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1310.00 USD | 539868.855% |
| Arch Therapeutics, Inc. | 5.64 Million USD | -25.186% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 83.476% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 2932.694% |
| Rebus Holdings, Inc. | 305 Thousand USD | -2218.351% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 212.157% |
| Qrons Inc. | 351.42 Thousand USD | -1912.074% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 622.36 Thousand USD | -1036.147% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 83.72% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 34748.04% |
| Skye Bioscience, Inc. | -5.72 Million USD | 223.588% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 55.142% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | -71.708% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -1659.609% |
| SQZ Biotechnologies Company | -36.23 Million USD | 119.513% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | -215.354% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | -662.627% |
| Mesoblast Limited | 55.85 Million USD | 87.341% |
| Marizyme, Inc. | 18.56 Million USD | 61.921% |
| Genus plc | 190.6 Million USD | 96.29% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | -216.257% |
| Pharming Group N.V. | 109.8 Million USD | 93.56% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | -721.976% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | -482.506% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | -939.849% |
| ContraFect Corporation | -6.02 Million USD | 217.341% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | -5151.801% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | -511.978% |
| IMV Inc. | 7.67 Million USD | 7.816% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | -28.519% |
| MultiCell Technologies, Inc. | 90.04 USD | -7853045.269% |
| ONE Bio Corp. | 9.04 Million USD | 21.782% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 1063.377% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 45.381% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | -416.895% |
| Q BioMed Inc. | 4.06 Million USD | -74.162% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 76.857% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | -601.683% |
| Biomind Labs Inc. | 711.4 Thousand USD | -893.949% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 88.321% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | -253.656% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 44.786% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -1865.742% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | -4957.775% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -35491.544% |
| Curative Biotechnology, Inc. | 2.2 Million USD | -221.119% |
| GB Sciences, Inc. | 1.74 Million USD | -304.676% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 3947.352% |
| HST Global, Inc. | 96.79 Thousand USD | -7205.251% |
| CSL Limited | 10.52 Billion USD | 99.933% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | -3328.899% |
| Halberd Corporation | 144.72 Thousand USD | -4785.934% |
| Enzolytics Inc. | 981.65 Thousand USD | -620.311% |
| Agentix Corp. | 37.63 Thousand USD | -18690.285% |
| Resverlogix Corp. | 6.45 Million USD | -9.61% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 1150.526% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -2.02 Billion USD | 100.349% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 115.041% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -161.055% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 179.989% |
| AVAX Technologies, Inc. | -5.9 Million USD | 219.782% |
| Zenith Capital Corp. | 10.06 Thousand USD | -70160.056% |
| Genscript Biotech Corporation | -1.06 Billion USD | 100.666% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | -3427.866% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | -196.348% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | -4198.228% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 38701.223% |
| Kadimastem Ltd | -253.1 Thousand USD | 2893.724% |
| Helix BioMedix, Inc. | -2.57 Million USD | 375.132% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 65.126% |
| BioStem Technologies, Inc. | 4.47 Million USD | -58.116% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | -3413.457% |
| LadRx Corporation | -2.03 Million USD | 447.217% |
| Cell Source, Inc. | 9.23 Million USD | 23.408% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -1013.246% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -1013.246% |
| NovAccess Global Inc. | 2.17 Million USD | -224.585% |
| Affymax, Inc. | -5.59 Million USD | 226.335% |
| Itoco Inc. | 228.3 Thousand USD | -2997.16% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | -5099.665% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | -42.646% |
| Mobile Lads Corp. | 484.23 Thousand USD | -1360.245% |
| CytoDyn Inc. | 20.26 Million USD | 65.102% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 1092985.935% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 76391.677% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 8.241% |
| SYBLEU INC | 473.71 Thousand USD | -1392.667% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | -58.648% |
| International Stem Cell Corporation | 2.59 Million USD | -173.011% |
| Bioxytran, Inc. | 1.89 Million USD | -272.369% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -11229.326% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -224.223% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | -105.911% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 17.328% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | -815.209% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 665.678% |
| Neutra Corp. | 52.18 Thousand USD | -13449.298% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 384.089% |
| PureTech Health plc | -167.19 Million USD | 104.229% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 2987.195% |
| IXICO plc | -4.44 Million USD | 259.092% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 46.509% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 87.109% |
| CSL Limited | 10.52 Billion USD | 99.933% |
| Cellectis S.A. | -43.81 Million USD | 116.137% |